Contact Evan Cantor, JD, MD

Request An Appointment

Evan Cantor, JD, MD

Director of Neuro-Oncology

Loading ratings
Practice Name Connecticut Children's Specialty Group


BS, Cornell University, 2004
JD, Albany Law School, 2007
MD, Medical School for International Health, 2014

Pediatrics, NYU-Winthrop, 2014-2017

Pediatric Hematology/Oncology, University of Michigan, 2017-2021
Pediatric Neuro-Oncology, Washington University in St. Louis, 2021-2022

Board Certifications

  • General Pediatrics, The American Academy of Pediatrics
  • Pediatric Hematology/Oncology (Pending), The American Academy of Pediatrics
  • Faculty Appointment

    Assistant Professor, Division of Pediatrics, University of Connecticut School of Medicine

    Clinical Expertise

    Evan Cantor, JD, MD, is a Neuro-Oncologist in the Center for Cancer and Blood Disorders at Connecticut Children’s. Dr. Cantor’s clinical interests include low and high-grade intracranial neoplasms. In his free time, Dr. Cantor enjoys reading, spending time with his family and Brazilian jiu-jitsu.

    Selected Publications

    • Cantor E, Koschmann C. “Multiplatform Molecular Profiling: A Precision Medicine Victory Built on Cytotoxic Chemotherapy” The Cancer Journal. 25(2):80, Mar 2019

    • Bruzek A, Ravi K, Muruganand A, Wadden J, Babila C, Cantor E, Tunkle L, Wierzbicki K, Stallard S, Dickson R, Wolfe I, Mody R, Schwartz J, Franson A, Robertson P, Muraszko K, Maher C, Garton H, Qin T, Koschmann C* (2020). Use of novel, hand-held, electronic DNA analysis platform to quantify multi-gene molecular response in CSF of patients with high-grade glioma. Clinical Cancer Research. 2020. DOI: 10.1158/1078-0432.CCR-20-2066

    • Pratt, D., Kumar-Sinha, C., Cieślik, M., Mehra, R., Xiao, H., Shao, L., Franson, A., Cantor, E., Chinnaiyan, A.M., Mody, R. and Abdullaev, Z., 2021. “A novel ATXN1-DUX4 fusion expands the spectrum of ‘CIC-rearranged sarcoma’of the CNS to include non-CIC alterations.” Acta Neuropathologica141(4), pp.619-622.

    • Cantor E, Wierzbicki K, Tarapore RS, Ravi K, Thomas C, Cartaxo R, Yadav VN, Ravindran R, Bruzek AK, Wadden J, John V, Babila CM, Cummings JR, Kawakibi AR, Ji S, Ramos J, Paul A, Walling D, Leonard M, Robertson P, Franson A, Mody R, Garton HJL, Venetti S, Odia Y, Kline C, Vitanza NA, Khatua S, Mueller S, Allen JE, Gardner S, Koschmann C. Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma. Neuro Oncol. 2022 Feb 6:noac030. doi: 10.1093/neuonc/noac030. Epub ahead of print. PMID: 35137228.

    • Cantor E, Meyer A, Morris SM, Weisenberg JLZ, Brossier NM. Dose-dependent seizure control with MEK inhibitor therapy for progressive glioma in a child with neurofibromatosis type 1. Childs Nerv Syst. 2022 Jun 1. doi: 10.1007/s00381-022-05571-y. Epub ahead of print. PMID: 35648241.

    Patient Feedback

    The Patient Rating score is an average of all responses to physician related questions on our nationally-recognized Patient Satisfaction Survey . Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments also are gathered from our Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.


    Back to Top
    Searching Animation